Entecavir is an antiviral drug

BARACLUDE is a nucleoside analogue indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

• Nucleoside-treatment-naïve with compensated liver disease (≥16 years old): 0.5 mg once daily.
• Lamivudine-refractory or known lamivudine or telbivudine resistance mutations (≥16 years old): 1 mg once daily.
• Decompensated liver disease (adults): 1 mg once daily.
• Renal impairment: Dosage adjustment is recommended if creatinine clearance is less than 50 mL/min.
• BARACLUDE should be administered on an empty stomach.

Most common adverse reactions (≥3%, all severity grades) are headache, fatigue, dizziness, and nausea.

None.

•Severe acute exacerbations of hepatitis B virus infection after discontinuation: Monitor hepatic function closely for at least several months.
• Co-infection with HIV: BARACLUDE is not recommended unless the patient is also receiving HAART.
• Lactic acidosis and severe hepatomegaly with steatosis: If suspected, treatment should be suspended.